ABVC BioPharma, Inc. (ABVC)

ABVC BioPharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	-	0.51	0.15	0.97	0.36
Revenue Growth (YoY)	-	234.31%	-84.28%	172.57%	-26.34%
Cost of Revenue	-	0	0.3	0.29	0.01
Gross Profit	-	0.51	-0.15	-0.68	0.35
Selling, General & Admin	2.89	2.26	5.37	6.07	5.75
Research & Development	0.12	0.18	1.06	2.69	1
Other Operating Expenses	4.14	2.77	0.19	7.04	5.31
Total Operating Expenses	7.15	5.21	6.62	15.8	12.06
Operating Income	-7.15	-4.71	-6.77	-15.11	-11.71
Interest Income	0.17	0.09	0.19	0.19	0.04
Interest Expense	-0.42	-0.83	-1.31	-0.29	-0.23
Other Non-Operating Income (Expense)	-0.95	0.07	-0.13	-0.29	0.68
Total Non-Operating Income (Expense)	-1.2	-0.66	-1.26	-0.4	0.5
Pretax Income	-8.35	-5.37	-8.02	-15.51	-11.21
Provision for Income Taxes	0.02	-0.11	0.26	0.8	0.83
Net Income	-7.91	-4.9	-7.79	-16.42	-12.84
Minority Interest in Earnings	-0.47	-0.36	-0.49	0.11	0.8
Net Income to Common	-7.91	-4.9	-7.79	-16.42	-12.84
Shares Outstanding (Basic)	20	12	4	3	25
Shares Outstanding (Diluted)	20	12	4	3	25
Shares Change (YoY)	72.25%	169.81%	36.64%	-87.36%	1170.75%
EPS (Basic)	-0.39	-0.42	-1.80	-5.19	-0.51
EPS (Diluted)	-0.39	-0.42	-1.80	-5.19	-0.51
Free Cash Flow	-2.99	-1.81	-4.21	-7.52	-7.62
Free Cash Flow Per Share	-0.15	-0.15	-	-2.37	-0.30
Gross Margin	-	99.85%	-98.15%	-70.47%	98.57%
Operating Margin	-	-923.34%	-4439.24%	-1558.54%	-3290.07%
Profit Margin	-	-1032.02%	-5432.56%	-1682.06%	-3382.79%
FCF Margin	-	-355.02%	-2760.64%	-775.23%	-2140.33%
EBITDA	-7.13	-4.67	-6.74	-15.09	-11.69
EBITDA Margin	-	-917.06%	-4420.52%	-1556.08%	-3286.70%
EBIT	-7.15	-4.71	-6.77	-15.11	-11.71
EBIT Margin	-	-923.34%	-4439.24%	-1558.54%	-3290.07%
Effective Tax Rate	-0.29%	2.06%	-3.19%	-5.14%	-7.36%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q